NASDAQ · QTRX
Healthcare · Medical - Devices
$2.81
Up+$0.15 (+5.34%)
Updated Nov 3, 2026, 7:04 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QTRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
QTRX closed at $2.81 after 21 trading sessions, down 26.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $2.94 | $2.94 | $2.735 | $2.81 | 514.27K |
| Oct 30, 2026 | $3.10 | $3.105 | $2.83 | $2.905 | 361.3K |
| Oct 29, 2026 | $3.11 | $3.21 | $3.095 | $3.145 | 334.19K |
| Oct 28, 2026 | $2.87 | $3.12 | $2.84 | $3.12 | 658.74K |
| Oct 27, 2026 | $2.86 | $2.96 | $2.82 | $2.89 | 467.7K |
| Oct 26, 2026 | $2.86 | $2.896 | $2.79 | $2.83 | 257.08K |
| Oct 23, 2026 | $2.82 | $2.88 | $2.71 | $2.86 | 349.8K |
| Oct 22, 2026 | $2.74 | $2.895 | $2.71 | $2.84 | 496.29K |
| Oct 21, 2026 | $2.71 | $2.815 | $2.675 | $2.79 | 525.25K |
| Oct 20, 2026 | $2.77 | $2.845 | $2.71 | $2.72 | 536.49K |
| Oct 19, 2026 | $2.87 | $2.93 | $2.72 | $2.77 | 430.15K |
| Oct 16, 2026 | $3.07 | $3.07 | $2.835 | $2.87 | 323.24K |
| Oct 15, 2026 | $3.05 | $3.105 | $2.92 | $3.07 | 291.06K |
| Oct 14, 2026 | $3.10 | $3.23 | $3.05 | $3.06 | 342.29K |
| Oct 13, 2026 | $3.17 | $3.335 | $3.11 | $3.15 | 749.92K |
| Oct 12, 2026 | $3.28 | $3.35 | $3.07 | $3.16 | 562.79K |
| Oct 9, 2026 | $3.22 | $3.445 | $3.20 | $3.28 | 282.66K |
| Oct 8, 2026 | $3.25 | $3.25 | $3.0613 | $3.21 | 607.39K |
| Oct 7, 2026 | $3.40 | $3.55 | $3.31 | $3.325 | 493.64K |
| Oct 6, 2026 | $3.83 | $3.98 | $3.42 | $3.44 | 606.57K |
| Oct 5, 2026 | $3.66 | $3.8968 | $3.62 | $3.81 | 1.03M |
The latest Smart Investors Daily articles mentioning QTRX.
Company
Market Activity
Research & News
QTRX research
Company profile and research snapshot.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Hold | — |
| Aug 17, 2026 | Canaccord Genuity | Hold | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| May 7, 2026 | TD Cowen | Hold | — |
| Apr 20, 2026 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 28, 2026
BILLERICA, Mass., October 28, 2026--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026 financial results.
Benzinga · Oct 13, 2026
TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and raises the price target from $3 to $3.5.
Yahoo · Oct 7, 2026
ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology.
Yahoo · Oct 7, 2026
ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced the expansion of its licensing agreement with Quanterix Corporation. The expanded agreement broadens the use of ALZpath's proprietary pTau217 antibody technology on Quanterix's Simoa® research platform, supporting continued innovation as the field advances toward increasingly precise blood-based approaches to understanding Alzheimer's disease pathology.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QTRX.
